Pharma

How-to Drive Patient Impact — Five Strategic Priorities for Medical Affairs

In today’s rapidly evolving healthcare landscape, Medical Affairs (MA) teams have taken on a pivotal role. They are no longer viewed as just support teams but are now essential in improving patient care, expanding access to treatments, and shaping the future of medicine. As healthcare becomes more complex, Medical Affairs is increasingly focusing on putting patients’ needs at the heart of every decision. By concentrating on five key areas, Medical Affairs can improve patient outcomes and strengthen the reputation of pharmaceutical companies.

23 Oct 2024

Medical Affairs — Shaping the Future of Pharma and Biotech

Medical Affairs (MA) is increasingly becoming a key player in pharmaceutical and biotechnology organisations, standing alongside Research & Development (R&D) and commercial operations. Traditionally viewed as a support function, MA now plays a crucial role in shaping corporate strategy by integrating scientific expertise, patient insights, and clinical data into decision-making processes.

9 Oct 2024

Breakfast Briefing Takeaways: How will Artificial Intelligence and Machine Learning Impact the Pharma Regulatory and Medical Affairs Space?

In PMC's first breakfast briefing of 2024, PharmaMedic's Managing Director, Dr Malcolm Barratt-Johnson was joined by guest speaker Dr Christine Grew, Director of Regulatory Affairs at Canopy Life Sciences to discuss machine learning and artificial intelligence, and a discussion on how this technology may impact our day-to-day roles.

30 Apr 2024

Join Our Free Breakfast Briefing: How will Artificial Intelligence and Machine Learning Impact the Pharma Regulatory and Medical Affairs Space?

Our next meeting on Wednesday, 24th April, 2024 will discuss machine learning and artificial intelligence and a discussion on how this technology may impact our day-to-day roles. Join Dr Malcolm Barratt-Johnson, Managing Director of PharmaMedic Consultancy and our guest speaker Dr Christine Grew, Director of Regulatory Affairs at Canopy Life Sciences.

5 Mar 2024

Government funds to grow UK life sciences workforce and upgrade science facility

As part of its £650m ‘Life Sci for Growth’ scheme to boost the life sciences sector and the wider economy, the government will establish a Medicines Manufacturing Skills Centre of Excellence with a dedicated £5.5m fund.

13 Sep 2023

UK rejoins Horizon Europe

Britain’s life science community is celebrating the country’s return to the EU Horizon Europe research programme, which was announced on 7 September 2023.

11 Sep 2023

Public and HCP trust in UK pharma industry maintained

The third annual Pharma Reputation Index, commissioned by the Association of the British Pharmaceutical Industry (ABPI), has found that the public looks favourably on the industry and continues to recognise its commitment to developing new medicines.

7 Sep 2023

MHRA consults on ending EC Decision Reliance Procedure

The Medicines and Healthcare products Regulatory Agency (MHRA) is inviting feedback on plans to end use of the European Commission Decision Reliance Procedure (ECDRP) to bring medicines to market.

4 Sep 2023

Still no UK-EU agreement on Horizon Europe

Roadblocks from the EU, and the UK government’s determination to get a ‘fair settlement’ on associate membership, are harming international collaborative research programmes and, ultimately, patients’ access to innovative treatments and devices.

16 Aug 2023

Clarification on continuation of CE marking in UK

The UK’s Department for Business and Trade (DBT) has announced an indefinite extension to the use of CE marking for businesses in the UK, beyond the 2024 deadline. The aim is to cut business costs and products’ time to market. The government intends to implement major reforms to the current regulatory framework for medical devices, with core parts set to apply from 1 July 2025.

7 Aug 2023